Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06987968 · ClinicalTrials.gov registry record · Phase 2
A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy
A Phase 2 study, sponsored by Genfit.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT06987968 is a Phase 2 study that was terminated before completion, run by Genfit. The registered enrollment target is 3 participants.
The verdict
NCT06987968, a Phase 2 study, was terminated before completion, sponsored by Genfit.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
A Phase 2, Randomized, Controlled, Open-Label, Adaptive Dose Design, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Two Different Dwell Times of VS-01 on Top of Standard of Care versus Standard of Care Alone in Patients with Overt Hepatic Encephalopathy
Interventions
- DRUG SOC
- DRUG VS-01 on top of SOC (Active Treatment Group)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2025-08-25 |
| Est. Completion | 2025-09-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06987968
The ClinicalTrials.gov registry entry for NCT06987968 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genfit, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SOC is the first listed.
NCT06987968 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06987968 about?
NCT06987968 is a clinical study titled "A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy". A Phase 2, Randomized, Controlled, Open-Label, Adaptive Dose Design, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Two Different Dwell Times of VS-01 on Top of Standard of Care versus Standard of Care Alone in Patients with Overt Hepatic Encephalopathy
What is the current status of trial NCT06987968?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2025-08-25. Estimated completion is 2025-09-15.
What interventions are being tested in trial NCT06987968?
The interventions under investigation include: SOC (DRUG), VS-01 on top of SOC (Active Treatment Group) (DRUG).
Who is sponsoring clinical trial NCT06987968?
This trial is sponsored by Genfit, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.